Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study.

Abstract

BACKGROUND AND PURPOSE:

Acamprosate is an anti-craving drug used for the pharmacotherapy of alcohol use disorder (AUD). However, only some patients achieve optimal therapeutic outcomes. This study was designed to explore differences in metabolomic profiles between patients who maintained sobriety and those who relapsed, to determine whether those differences provide insight into variation in acamprosate treatment response phenotypes.

EXPERIMENTAL APPROACH:

We previously conducted an acamprosate trial involving 442 AUD patients, and 267 of these subjects presented themselves for a 3-month follow-up. The primary outcome was abstinence. Clinical information, genomic data and metabolomics data were collected. Baseline plasma samples were assayed using targeted metabolomics.

KEY RESULTS:

Baseline plasma arginine, threonine, α-aminoadipic acid and ethanolamine concentrations were associated with acamprosate treatment outcomes and baseline craving intensity, a measure that has been associated with acamprosate treatment response. We next applied a pharmacometabolomics-informed genome-wide association study (GWAS) strategy to identify genetic variants that might contribute to variations in plasma metabolomic profiles that were associated with craving and/or acamprosate treatment outcome. Gene expression data for induced pluripotent stem cell-derived forebrain astrocytes showed that a series of genes identified during the metabolomics-informed GWAS were ethanol responsive. Furthermore, a large number of those genes could be regulated by acamprosate. Finally, we identified a series of single nucleotide polymorphisms that were associated with acamprosate treatment outcomes.

CONCLUSION AND IMPLICATIONS:

These results serve as an important step towards advancing our understanding of disease pathophysiology and drug action responsible for variation in acamprosate response and alcohol craving in AUD patients.

• Authors: Ming-Fen Ho, Cheng Zhang, Lixuan Wei, Lingxin Zhang, Irene Moon, Jennifer R Geske, Michelle K Skime, Doo-Sup Choi, Joanna M Biernacka, Tyler S Oesterle, Mark A Frye, Marvin D Seppala, Victor M Karpyak, Hu Li, Richard M Weinshilboum
• Journal: British journal of pharmacology (Br J Pharmacol) Vol. 179 Issue 13 Pg. 3330-3345 (07 2022) ISSN: 1476-5381 [Electronic] England
• PMID: 35016259 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: © 2022 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

Chemical References

• Alcohol Deterrents
• Taurine
• Ethanol
• Acamprosate

Topics

• Acamprosate (therapeutic use)
• Alcohol Deterrents (therapeutic use)
• Alcohol Drinking
• Alcoholism (drug therapy, genetics)
• Ethanol
• Genome-Wide Association Study
• Humans
• Taurine (therapeutic use)